Kestra Advisory Services’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Kestra Advisory Services’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,672	Closed	-$218K	–	2207
2023 Q1	$218K	Sell	7,672 -167	-2%	-$4.96K	﹤0.01%	1782
2022 Q4	$229K	Buy	7,839 +88	+1%	+$2.8K	﹤0.01%	1937
2022 Q3	$205K	Buy	7,751 +8	+0.1%	+$294	﹤0.01%	1867
2022 Q2	$344K	Buy	7,743 +66	+0.9%	+$3.03K	﹤0.01%	1541
2022 Q1	$380K	Sell	7,677 -119	-2%	-$5.71K	﹤0.01%	1447
2021 Q4	$397K	Buy	7,796 +2	+0%	+$104	﹤0.01%	1438
2021 Q3	$435K	Buy	7,794 +3	+0%	+$148	﹤0.01%	1460
2021 Q2	$333K	Sell	7,791 -76	-1%	-$3.14K	﹤0.01%	1506
2021 Q1	$328K	Buy	7,867 +362	+5%	+$16.8K	﹤0.01%	1414
2020 Q4	$349K	Buy	7,505 +7,400	+7,048%	+$346K	﹤0.01%	1394
2020 Q3	$310K	Buy	+105	New	+$4.59K	0.01%	1095

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kestra Advisory Services's EGRX Position: Q2 2023 in Review

Kestra Advisory Services sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 7,672 shares — an estimated $218K sold.

Kestra Advisory Services first reported a position in EGRX in Q3 2020 and held it in 11 quarters. The position peaked at $435K in Q3 2021. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

Kestra Advisory Services reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Kestra Advisory Services sold 7,672 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $218K.
Kestra Advisory Services first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2020 and held it in 11 quarters.
Kestra Advisory Services's Eagle Pharmaceuticals, Inc. position peaked at $435K in Q3 2021.
126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Kestra Advisory Services's 13F filing for Q2 2023, filed 11 Aug 2023.